ADMA Biologics Inc vs Albemarle Corp. — how do they compare? ADMA Biologics Inc trades at $9.81 (market cap $2.22B), while Albemarle Corp. trades at $131.06 (market cap $15.27B). The key difference: Albemarle Corp. is far larger — about 6.9× ADMA Biologics Inc's market cap, and Albemarle Corp. pays a 1.27% dividend while ADMA Biologics Inc pays none. Which is the better fit depends on your goals.
| ADMA | ALB | |
|---|---|---|
Market Cap | $2.22B | $15.27B |
Sector | Health | Basic Materials |
52-Week High | $20.38 | $215.62 |
52-Week Low | $7.60 | $72.58 |
Enterprise Value | $2.29B | $17.75B |
Dividend Yield | — | 1.27% |
Trailing returns across standard periods
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →Albemarle is the world's largest lithium producer. Our outlook for robust lithium demand is predicated upon increased demand for electric vehicle batteries. Albemarle produces lithium from its salt brine deposits in Chile and the U.S. and its hard rock joint venture mines in Australia. Albemarle is also a global leader in the production of bromine, used in flame retardants. The company is also a major producer of oil refining catalysts.
Read more on ALB →